Page last updated: 2024-10-27

fexofenadine and Hives

fexofenadine has been researched along with Hives in 58 studies

fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl
fexofenadine : A piperidine-based anti-histamine compound.

Research Excerpts

ExcerptRelevanceReference
"H1-antihistamines are the first-line treatment of chronic idiopathic urticaria (CIU), but CIU is occasionally refractory to the conventional treatment doses."9.17Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations. ( Kabashima, K; Miyachi, Y; Nakahigashi, K; Tanizaki, H, 2013)
"The present study examined the impact of once-daily fexofenadine hydrochloride (HCl) 180 mg on health-related quality of life (HRQL) in subjects with chronic idiopathic urticaria (CIU)."9.12The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. ( Harding, G; Leahy, MJ; Meeves, S; Shikiar, R; Spector, SL, 2007)
"The effect of 60 mg twice-daily fexofenadine HCl on health-related quality of life and productivity at work, in the classroom, and during daily activities in patients with moderate to severe chronic idiopathic urticaria symptoms was studied in two identical, 4-week, placebo-controlled, multicenter clinical trials."9.09Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. ( Finn, AF; Schoenwetter, WF; Thompson, AK, 2000)
"Fexofenadine HCl significantly reduced pruritus severity, number of wheals, and interference with sleep and normal daily activities in patients with chronic urticaria compared with placebo."9.09Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. ( Mason, J; Nelson, HS; Reynolds, R, 2000)
"Fexofenadine HCl is well tolerated and is statistically superior to placebo in reducing signs and symptoms of CIU and in ameliorating interference with sleep and daily activities due to urticaria."9.09A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. ( Finn, AF; Fretwell, R; Kaplan, AP; Long, J; Qu, R, 1999)
"A 40-year-old male medical student presented with urticarial vasculitis secondary to occupational formaldehyde exposure."7.74Formaldehyde-induced urticarial vasculitis. ( Marshman, G; Pellizzari, M, 2007)
"fexofenadine is clinically effective in the treatment of seasonal allergic rhinitis and chronic idiopathic urticaria for which it is a suitable option for first-line therapy."7.70Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. ( Jarvis, B; Simpson, K, 2000)
"To evaluate the efficacy and safety of once-daily dosing of fexofenadine hydrochloride, 180 mg, on CIU."6.71Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. ( Georges, G; Kaplan, AP; Liao, Y; Meeves, S; Spector, SL; Varghese, ST, 2005)
"Fexofenadine is a non-sedating antihistamine indicated for relieving symptoms from allergic conditions with a rapid onset of action without cardiotoxic risks."6.70Multicenter study of the efficacy and safety of fexofenadine 60 mg. twice daily in 108 Thai patients with chronic idiopathic urticaria. ( Aunhachoke, K; Charuwichitratana, S; Gherunpong, N; Gritiyarangsan, P; Janjumratsang, P; Jiamton, S; Korkij, W; Krisadapong, J; Kullavanijaya, P; Kulthanan, K; Kuntiranont, M; Sitakalin, C, 2001)
"Fexofenadine 180 mg is a new antihistamine that is effective in the treatment of chronic urticaria and that has a profile of side effects similar to placebo."6.70[Chronic idiopathic urticaria: effectiveness of fexofenadine. A double-blind, placebo controlled study with 21 patients]. ( Bircher, A; Degonda, M; Helbling, A; Pichler, WJ, 2002)
"Urticaria is a common clinical condition that gives a major concern for physicians and patients alike."5.56Efficacy of Fexofenadine in the Treatment of Chronic Idiopathic Urticaria. ( Akhter, F; Jahan, H; Nandi, AK, 2020)
" Fexofenadine given in the conventional dosage can prevent recurrences and represents a successful treatment measure when dealing with this peculiar form of solar urticaria."5.31Fixed solar urticaria to visible light successfully treated with fexofenadine. ( Bazex, J; Journé, F; Loche, E; Marguery, MC; Schwarze, HP, 2001)
"H1-antihistamines are the first-line treatment of chronic idiopathic urticaria (CIU), but CIU is occasionally refractory to the conventional treatment doses."5.17Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations. ( Kabashima, K; Miyachi, Y; Nakahigashi, K; Tanizaki, H, 2013)
"Nonsedating antihistamines (nsAHs) are recommended as first-line therapeutics for the treatment of mast cell-driven disorders, including allergic rhinitis and urticaria."5.14Suppression of histamine- and allergen-induced skin reactions: comparison of first- and second-generation antihistamines. ( dos Santos, RV; Lima, HC; Magerl, M; Mlynek, A, 2009)
"The present study examined the impact of once-daily fexofenadine hydrochloride (HCl) 180 mg on health-related quality of life (HRQL) in subjects with chronic idiopathic urticaria (CIU)."5.12The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. ( Harding, G; Leahy, MJ; Meeves, S; Shikiar, R; Spector, SL, 2007)
"Levocetirizine is the active enantiomer of cetirizine, a potent drug with little metabolism widely used for allergic rhinitis and urticaria."5.10A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. ( DeVos, C; Grant, JA; Moulaert, B; Riethuisen, JM, 2002)
"Fexofenadine HCl is well tolerated and is statistically superior to placebo in reducing signs and symptoms of CIU and in ameliorating interference with sleep and daily activities due to urticaria."5.09A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. ( Finn, AF; Fretwell, R; Kaplan, AP; Long, J; Qu, R, 1999)
"Fexofenadine HCl significantly reduced pruritus severity, number of wheals, and interference with sleep and normal daily activities in patients with chronic urticaria compared with placebo."5.09Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. ( Mason, J; Nelson, HS; Reynolds, R, 2000)
"Pretreatment with fexofenadine during venom immunotherapy reduces local allergic reactions and generalized symptoms of the urticaria and angioedema type."5.09Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. ( Hari, Y; Müller, U; Reimers, A, 2000)
"The effect of 60 mg twice-daily fexofenadine HCl on health-related quality of life and productivity at work, in the classroom, and during daily activities in patients with moderate to severe chronic idiopathic urticaria symptoms was studied in two identical, 4-week, placebo-controlled, multicenter clinical trials."5.09Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. ( Finn, AF; Schoenwetter, WF; Thompson, AK, 2000)
"Urticaria is mainly caused by mast cell-derived histamine through the histamine H(1) receptor."3.78Effects of bepotastine and fexofenadine on histamine-induced flare, wheal and itch. ( Fukuoka, M; Ikoma, A; Kabashima, K; Miyachi, Y; Tanizaki, H, 2012)
" We report a patient with urticaria due to ingestion of ebastine and fexofenadine."3.77Urticaria due to antihistamines. ( Laguna Martínez, JJ; Reaño Martos, M; Rojas Pérez-Ezquerra, P; Sánchez Morillas, L; Sanz, ML, 2011)
"A 40-year-old male medical student presented with urticarial vasculitis secondary to occupational formaldehyde exposure."3.74Formaldehyde-induced urticarial vasculitis. ( Marshman, G; Pellizzari, M, 2007)
"fexofenadine is clinically effective in the treatment of seasonal allergic rhinitis and chronic idiopathic urticaria for which it is a suitable option for first-line therapy."3.70Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. ( Jarvis, B; Simpson, K, 2000)
" However, the effect of long-term use of montelukast, a cystenil leukotriene receptor antagonist, on skin prick test hasn't been full elucidated."2.78The effect of montelukast on wheal reactions in skin prick tests: a double-blind-placebo-controlled randomized trial. ( Aydogan, M; Aydogmus, CY; Bulan, K; Siraneci, R, 2013)
"Levocetirizine was more inhibitory than fexofenadine on wheal, flare and pruritus (p < 0."2.78The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers. ( Church, MK; Maurer, M; Schoepke, N, 2013)
"Fexofenadine (180 mg/d) was taken during the run-in period and subsequently throughout the study and follow-up as required."2.73Narrowband ultraviolet B phototherapy is beneficial in antihistamine-resistant symptomatic dermographism: a pilot study. ( Borzova, E; Grattan, CE; Konstantinou, GN; Leslie, KS; Rutherford, A, 2008)
"To evaluate the efficacy and safety of once-daily dosing of fexofenadine hydrochloride, 180 mg, on CIU."2.71Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. ( Georges, G; Kaplan, AP; Liao, Y; Meeves, S; Spector, SL; Varghese, ST, 2005)
"Loratadine was statistically no different from placebo in terms of both overall wheal and flare suppression."2.71Suppression of the histamine-induced wheal and flare response by fexofenadine HCl 60 mg twice daily, loratadine 10 mg once daily and placebo in healthy Japanese volunteers. ( Boyle, J; Hindmarch, I; Johnsen, S; Meadows, R; Ridout, F, 2005)
"Fexofenadine is a non-sedating antihistamine indicated for relieving symptoms from allergic conditions with a rapid onset of action without cardiotoxic risks."2.70Multicenter study of the efficacy and safety of fexofenadine 60 mg. twice daily in 108 Thai patients with chronic idiopathic urticaria. ( Aunhachoke, K; Charuwichitratana, S; Gherunpong, N; Gritiyarangsan, P; Janjumratsang, P; Jiamton, S; Korkij, W; Krisadapong, J; Kullavanijaya, P; Kulthanan, K; Kuntiranont, M; Sitakalin, C, 2001)
"Fexofenadine 180 mg is a new antihistamine that is effective in the treatment of chronic urticaria and that has a profile of side effects similar to placebo."2.70[Chronic idiopathic urticaria: effectiveness of fexofenadine. A double-blind, placebo controlled study with 21 patients]. ( Bircher, A; Degonda, M; Helbling, A; Pichler, WJ, 2002)
"Ebastine was no better than placebo until 4 h, but was efficacious thereafter until 24 h."2.69A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. ( Danielson, L; DeVos, C; Grant, JA; Rihoux, JP, 1999)
"Guidelines for the treatment of urticaria issued by Polish and international expert bodies were analyzed, along with the SPCs."2.49[Pharmacotherapy of urticaria--an analysis of the discrepancies between guidelines of expert bodies, registration documents and evidence for the effectiveness of drugs]. ( Plichta, D; Spiewak, R, 2013)
" No major cytochrome P450 inhibition has been reported with desloratadine, fexofenadine and levocetirizine, and the bioavailability of desloratadine is minimally affected by drugs interfering with transporter molecules."2.44Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. ( Devillier, P; Faisy, C; Roche, N, 2008)
"Urticaria is a common clinical condition that gives a major concern for physicians and patients alike."1.56Efficacy of Fexofenadine in the Treatment of Chronic Idiopathic Urticaria. ( Akhter, F; Jahan, H; Nandi, AK, 2020)
" In cases of failure, treatment was switched to omalizumab at doses of < 300 mg/month with incremental dosage increases as necessary (monthly dose range, 150-600 mg/month)."1.51Real-life experience in the treatment of solar urticaria: retrospective cohort study. ( Enk, CD; Hodak, E; Lapidoth, M; Levi, A; Mazor, S; Snast, I; Uvaidov, V, 2019)
" It is concluded that estimating in vivo receptor occupancy, which takes into account both the affinity of the drug for the receptor and its free plasma concentration, is a far better predictor for human pharmacodynamics and hence antihistamine potency, than considering in vitro affinity and plasmatic half-life only."1.33Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. ( Baltes, E; Benedetti, MS; Chatelain, P; Gillard, M, 2005)
" Fexofenadine given in the conventional dosage can prevent recurrences and represents a successful treatment measure when dealing with this peculiar form of solar urticaria."1.31Fixed solar urticaria to visible light successfully treated with fexofenadine. ( Bazex, J; Journé, F; Loche, E; Marguery, MC; Schwarze, HP, 2001)

Research

Studies (58)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (6.90)18.2507
2000's37 (63.79)29.6817
2010's15 (25.86)24.3611
2020's2 (3.45)2.80

Authors

AuthorsStudies
Jahan, H1
Akhter, F1
Nandi, AK1
Hassan, K1
Snast, I1
Lapidoth, M1
Uvaidov, V1
Enk, CD2
Mazor, S1
Hodak, E1
Levi, A2
Hassoun, Y1
Stevenson, MR1
Bernstein, DI1
Tanizaki, H3
Nakahigashi, K1
Miyachi, Y3
Kabashima, K3
Bulan, K1
Aydogan, M1
Siraneci, R1
Aydogmus, CY1
Plichta, D1
Spiewak, R1
Guo, A1
Zhu, W1
Zhang, C1
Wen, S1
Chen, X2
Chen, M1
Zhang, J1
Su, J1
Chen, W1
Zhao, Y1
Yan, S1
He, Y1
Liu, Z1
Zhou, H1
Li, J1
Yamamoto, Y1
Nakamizo, S1
Otsuka, A1
Hirohata, A1
Yamaoka, T1
Hayashi, M1
Murota, H1
Tani, M1
Katayama, I1
Hama, N1
Shimomura, Y1
Arinami, H1
Maruyama, R1
Abe, R1
Izumi, N1
Mizuguchi, H1
Umehara, H1
Ogino, S1
Fukui, H1
Borzova, E1
Rutherford, A1
Konstantinou, GN1
Leslie, KS1
Grattan, CE1
Inomata, N1
Tatewaki, S1
Ikezawa, Z1
dos Santos, RV1
Magerl, M1
Mlynek, A1
Lima, HC1
Shaikh, WA1
Shaikh, SW1
Sánchez Morillas, L1
Rojas Pérez-Ezquerra, P1
Reaño Martos, M1
Sanz, ML1
Laguna Martínez, JJ1
Kamei, H1
Isaji, A1
Noda, Y1
Ishikawa, K1
Senzaki, K1
Yamada, K1
Sugiura, K1
Tomita, Y1
Nabeshima, T1
Ikoma, A1
Fukuoka, M1
Church, MK2
Maurer, M2
Schoepke, N1
Chowdhury, BA1
Cassano, N1
Filotico, R1
D'Argento, V1
Filieri, M1
Coviello, C1
Vena, G1
Kawashima, M1
Harada, S1
Tango, T1
Mekkes, JR1
de Vries, HJ1
Kammeyer, A1
Duchateau, J1
Heenen, M1
Sternon, J1
Handa, S1
Dogra, S1
Kumar, B1
Roongapinun, S1
Wajajamreon, S1
Fooanant, S1
Lennox, RD2
Leahy, MJ2
Purohit, A1
N'Gom, AS1
Deslandes, B1
Pauli, G1
Frossard, N1
Shikiar, R2
Harding, G2
Leahy, M1
Kaplan, AP2
Spector, SL2
Meeves, S2
Liao, Y1
Varghese, ST2
Georges, G2
Dhar, S1
Boyle, J1
Ridout, F1
Meadows, R1
Johnsen, S1
Hindmarch, I1
Gillard, M1
Benedetti, MS1
Chatelain, P1
Baltes, E1
Kłos, K2
Kruszewski, J2
Kruszewski, R1
Sułek, K2
Pellizzari, M1
Marshman, G1
Benhamou, AH1
Vanini, G1
Lantin, JP1
Eigenmann, PA1
Takahashi, H1
Zhang, Y1
Morita, E1
Devillier, P1
Roche, N1
Faisy, C1
De Vos, C1
Mitchev, K1
Pinelli, ME1
Derde, MP1
Boev, R1
Paul, E1
Markham, A1
Wagstaff, AJ1
Grant, JA2
Danielson, L1
Rihoux, JP1
DeVos, C2
Finn, AF2
Fretwell, R1
Qu, R1
Long, J1
Simpson, K1
Jarvis, B1
Nelson, HS1
Reynolds, R1
Mason, J1
Reimers, A1
Hari, Y1
Müller, U1
Thompson, AK1
Schoenwetter, WF1
Schwarze, HP1
Marguery, MC1
Journé, F1
Loche, E1
Bazex, J1
Nettis, E1
Dambra, P1
D'Oronzio, L1
Loria, MP1
Ferrannini, A1
Tursi, A1
Amichai, B1
Grunwald, MH1
Brenner, L1
Kulthanan, K1
Gritiyarangsan, P1
Sitakalin, C1
Charuwichitratana, S1
Korkij, W1
Aunhachoke, K1
Janjumratsang, P1
Jiamton, S1
Kuntiranont, M1
Krisadapong, J1
Gherunpong, N1
Kullavanijaya, P1
Riethuisen, JM1
Moulaert, B1
Degonda, M1
Pichler, WJ1
Bircher, A1
Helbling, A1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Observational Study of the Prevalence of Antihistamine Responsive Gastrointestinal Symptoms in Patients Diagnosed With Irritable Bowel Syndrome With Diarrhea[NCT04612803]100 participants (Anticipated)Observational2020-11-15Not yet recruiting
Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg Once Daily With Fexofenadine 60 mg Twice Daily in the Histamine Induced Wheal, Flare and Itch Response[NCT01586091]Phase 418 participants (Actual)Interventional2011-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Flaire Diameter (mm)

Flaire diameter was measured with a transparent ruler as the mean of the largest diameter and the diameter at right angles to this. (NCT01586091)
Timeframe: 24 hours per treatment

Interventionmm (Mean)
Placebo69.4
Levocetirizin20.4
Fexofenadine39.9

Pruritus as Assessed by the VAS Score

"We measured drug concentrations and various aspects of skin provocation testing such as itch intensity and wheal size. Measurements made at each time point were as followed: Pruritus was assessed every 30 s for 10 min after SPT using a visual analogue scale (VAS) score with a 0 and 100 at the two ex- tremes of an unmarked 100 mm line with higher values indicating greater puritus. The mean VAS for each 10 min was calculated and used as a primary end Point." (NCT01586091)
Timeframe: up to 10 minutes after skin prick test performed 24 hours after drug administration

Interventionmm (Mean)
Levocetirizin11.5
Fexofenadine25.4
Placebo46.0

Wheal Volume (cm3)

Wheal volume was measured by a non-contact three dimensional measurement system (PRIMOS contact, GFM Messtechnik GmbH, Teltow, Germany). (NCT01586091)
Timeframe: 24 hours per treatment

Interventioncm3 (Mean)
Placebo174.6
Levocetirizin35.2
Fexofenadine106.3

Reviews

7 reviews available for fexofenadine and Hives

ArticleYear
[Pharmacotherapy of urticaria--an analysis of the discrepancies between guidelines of expert bodies, registration documents and evidence for the effectiveness of drugs].
    Przeglad lekarski, 2013, Volume: 70, Issue:12

    Topics: Administration, Oral; Administration, Topical; Anti-Allergic Agents; Benzimidazoles; Cetirizine; Glu

2013
H(1)-antihistamines and urticaria: how can we predict the best drug for our patient?
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2012, Volume: 42, Issue:10

    Topics: Anti-Allergic Agents; Cetirizine; Histamine; Histamine H1 Antagonists, Non-Sedating; Humans; Loratad

2012
Review of fexofenadine in the treatment of chronic idiopathic urticaria.
    International journal of dermatology, 2002, Volume: 41, Issue:10

    Topics: Anti-Allergic Agents; Asia; Chronic Disease; Humans; North America; Terfenadine; Urticaria

2002
[H1 histamine antagonists].
    Revue medicale de Bruxelles, 2003, Volume: 24, Issue:2

    Topics: Acetates; Anti-Allergic Agents; Cetirizine; Chemistry, Pharmaceutical; Histamine H1 Antagonists; Hum

2003
Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.
    Clinical pharmacokinetics, 2008, Volume: 47, Issue:4

    Topics: Cetirizine; Drug Interactions; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Rhinitis,

2008
Fexofenadine.
    Drugs, 1998, Volume: 55, Issue:2

    Topics: Animals; Histamine Antagonists; Humans; Rhinitis, Allergic, Seasonal; Terfenadine; Urticaria

1998
Fexofenadine hydrochloride--a new anti-histaminic drug.
    The Israel Medical Association journal : IMAJ, 2001, Volume: 3, Issue:3

    Topics: Chronic Disease; Clinical Trials as Topic; Drug Interactions; Histamine H1 Antagonists; Humans; Pati

2001

Trials

27 trials available for fexofenadine and Hives

ArticleYear
Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations.
    The Journal of dermatological treatment, 2013, Volume: 24, Issue:6

    Topics: Adult; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Histamine; Histamine H1 Ant

2013
The effect of montelukast on wheal reactions in skin prick tests: a double-blind-placebo-controlled randomized trial.
    International journal of pediatric otorhinolaryngology, 2013, Volume: 77, Issue:10

    Topics: Acetates; Allergens; Animals; Asthma; Chi-Square Distribution; Child; Cyclopropanes; Dose-Response R

2013
Association of FCER1A genetic polymorphisms with risk for chronic spontaneous urticaria and efficacy of nonsedating H1-antihistamines in Chinese patients.
    Archives of dermatological research, 2015, Volume: 307, Issue:2

    Topics: Adult; Asian People; Benzimidazoles; China; Female; Genotyping Techniques; Histamine H1 Antagonists,

2015
Comparison of the efficacy of olopatadine and fexofenadine in chronic idiopathic urticaria patients: a crossover study.
    Pharmacology, 2015, Volume: 95, Issue:1-2

    Topics: Adult; Anti-Allergic Agents; Chronic Disease; Cross-Over Studies; Dibenzoxepins; Female; Histamine H

2015
Narrowband ultraviolet B phototherapy is beneficial in antihistamine-resistant symptomatic dermographism: a pilot study.
    Journal of the American Academy of Dermatology, 2008, Volume: 59, Issue:5

    Topics: Adult; Drug Resistance; Female; Histamine H1 Antagonists; Humans; Male; Pilot Projects; Prospective

2008
Suppression of histamine- and allergen-induced skin reactions: comparison of first- and second-generation antihistamines.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2009, Volume: 102, Issue:6

    Topics: Adult; Allergens; Animals; Dermatophagoides pteronyssinus; Dibenzazepines; Double-Blind Method; Fema

2009
Effects of single therapeutic doses of promethazine, fexofenadine and olopatadine on psychomotor function and histamine-induced wheal- and flare-responses: a randomized double-blind, placebo-controlled study in healthy volunteers.
    Archives of dermatological research, 2012, Volume: 304, Issue:4

    Topics: Adolescent; Dibenzoxepins; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Male; Olop

2012
The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers.
    Acta dermato-venereologica, 2013, Volume: 93, Issue:3

    Topics: Adult; Asian People; Cetirizine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind

2013
Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria.
    The Journal of dermatological treatment, 2004, Volume: 15, Issue:1

    Topics: Adolescent; Adult; Aged; Cetirizine; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Seda

2004
Comparative efficacy of wheal-and-flare suppression among various non-sedating antihistamines and the pharmacologic insights to their efficacy.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2004, Volume: 87, Issue:5

    Topics: Adolescent; Adult; Cetirizine; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; M

2004
Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2004, Volume: 93, Issue:2

    Topics: Chronic Disease; Dermatology; Dose-Response Relationship, Drug; Double-Blind Method; Histamine H1 An

2004
Similar rapid onset of action and magnitude of effect of fexofenadine and cetirizine as assessed by inhibition of histamine-induced wheal-and-flare reaction.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2004, Volume: 93, Issue:6

    Topics: Adolescent; Adult; Cetirizine; Cross-Over Studies; Female; Histamine; Histamine H1 Antagonists; Huma

2004
Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2005, Volume: 94, Issue:6

    Topics: Adolescent; Child; Chronic Disease; Double-Blind Method; Female; Humans; Male; Terfenadine; Urticari

2005
Suppression of the histamine-induced wheal and flare response by fexofenadine HCl 60 mg twice daily, loratadine 10 mg once daily and placebo in healthy Japanese volunteers.
    Current medical research and opinion, 2005, Volume: 21, Issue:9

    Topics: Adult; Drug Therapy, Combination; Female; Histamine H1 Antagonists; Humans; Japan; Loratadine; Male;

2005
[The effect of 5-days of cetirizine, desloratadine, fexofenadine 120 and 180 mg, levocetirizine, loratadine treatment on the histamine-induced skin reaction and skin blood flow--a randomized, double-blind, placebo controlled trial].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2006, Volume: 21, Issue:125

    Topics: Administration, Oral; Adult; Cetirizine; Double-Blind Method; Drug Administration Schedule; Histamin

2006
[Inhibition of histamine-induced wheel after a recommended single dose administration of 10 mg cetirizine, 5 mg desloratadine, 120 i 180 mg fexofenadine, 5 mg levocetirizine and 10 mg loratadine--a randomized, double-blind, placebo controlled trial].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2006, Volume: 21, Issue:125

    Topics: Administration, Oral; Adult; Cetirizine; Double-Blind Method; Histamine; Histamine H1 Antagonists, N

2006
The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria.
    Cutis, 2007, Volume: 79, Issue:2

    Topics: Adolescent; Chronic Disease; Double-Blind Method; Efficiency; Female; Histamine H1 Antagonists, Non-

2007
Evaluation of the antihistamine effects of olopatadine, cetirizine and fexofenadine during a 24 h period: a double-blind, randomized, crossover, placebo-controlled comparison in skin responses induced by histamine iontophoresis.
    Archives of dermatological research, 2008, Volume: 300, Issue:6

    Topics: Adult; Cetirizine; Cross-Over Studies; Dibenzoxepins; Dose-Response Relationship, Drug; Double-Blind

2008
A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects.
    Allergy, 1999, Volume: 54, Issue:7

    Topics: Adult; Butyrophenones; Cetirizine; Cross-Over Studies; Dibenzazepines; Double-Blind Method; Histamin

1999
A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria.
    The Journal of allergy and clinical immunology, 1999, Volume: 104, Issue:5

    Topics: Adolescent; Adult; Aged; Child; Chronic Disease; Double-Blind Method; Female; Histamine H1 Antagonis

1999
Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2000, Volume: 84, Issue:5

    Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Child; Chronic Disease; Disorders of Excessive Somnol

2000
Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial.
    Allergy, 2000, Volume: 55, Issue:5

    Topics: Adolescent; Adult; Angioedema; Anti-Allergic Agents; Bee Venoms; Double-Blind Method; Drug Therapy,

2000
Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria.
    Journal of the American Academy of Dermatology, 2000, Volume: 43, Issue:1 Pt 1

    Topics: Adolescent; Adult; Aged; Chronic Disease; Female; Histamine H1 Antagonists; Humans; Male; Middle Age

2000
Comparison of montelukast and fexofenadine for chronic idiopathic urticaria.
    Archives of dermatology, 2001, Volume: 137, Issue:1

    Topics: Acetates; Adult; Aged; Chronic Disease; Cyclopropanes; Double-Blind Method; Female; Histamine H1 Ant

2001
Multicenter study of the efficacy and safety of fexofenadine 60 mg. twice daily in 108 Thai patients with chronic idiopathic urticaria.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2001, Volume: 84, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Histamine H1 Antagonists; Human

2001
A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2002, Volume: 88, Issue:2

    Topics: Adult; Benzimidazoles; Butyrophenones; Cetirizine; Cross-Over Studies; Double-Blind Method; Histamin

2002
[Chronic idiopathic urticaria: effectiveness of fexofenadine. A double-blind, placebo controlled study with 21 patients].
    Praxis, 2002, Apr-10, Volume: 91, Issue:15

    Topics: Adult; Aged; Anti-Allergic Agents; Chronic Disease; Double-Blind Method; Female; Humans; Male; Middl

2002

Other Studies

24 other studies available for fexofenadine and Hives

ArticleYear
Efficacy of Fexofenadine in the Treatment of Chronic Idiopathic Urticaria.
    Mymensingh medical journal : MMJ, 2020, Volume: 29, Issue:2

    Topics: Adolescent; Bangladesh; Chronic Disease; Chronic Urticaria; Double-Blind Method; Humans; Terfenadine

2020
Urticaria and angioedema as a prodromal cutaneous manifestation of SARS-CoV-2 (COVID-19) infection.
    BMJ case reports, 2020, Jul-07, Volume: 13, Issue:7

    Topics: Angioedema; Anti-Allergic Agents; Betacoronavirus; Chlorpheniramine; Coronavirus Infections; COVID-1

2020
Real-life experience in the treatment of solar urticaria: retrospective cohort study.
    Clinical and experimental dermatology, 2019, Volume: 44, Issue:5

    Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Cetirizine; Child; Cohort Studies; Cyclopro

2019
Idiopathic postprandial diarrhea responsive to antihistamines.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2019, Volume: 123, Issue:4

    Topics: Adult; Angioedema; Cetirizine; Diarrhea; Famotidine; Female; Food Hypersensitivity; Histamine Antago

2019
Treatment of solar urticaria using antihistamine and leukotriene receptor antagonist combinations tailored to disease severity.
    Photodermatology, photoimmunology & photomedicine, 2015, Volume: 31, Issue:6

    Topics: Acetates; Adolescent; Adult; Cetirizine; Child; Child, Preschool; Cyclopropanes; Drug Therapy, Combi

2015
Unique case of postural cholinergic urticaria induced by a standing position.
    Clinical and experimental dermatology, 2016, Volume: 41, Issue:4

    Topics: Acetylcholine; Adolescent; Diphenhydramine; Humans; Male; Posture; Terfenadine; Urticaria

2016
Localized heat urticaria: Positive reaction of preheated autologous serum skin test.
    The Journal of dermatology, 2016, Volume: 43, Issue:9

    Topics: Anaphylaxis; Chlorpheniramine; Desensitization, Immunologic; Drug Therapy, Combination; Histamine H1

2016
Analysis of disease-dependent sedative profiles of H(1)-antihistamines by large-scale surveillance using the visual analog scale.
    Methods and findings in experimental and clinical pharmacology, 2008, Volume: 30, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asthma; Butyrophenones; Cetirizine; Child; Chlorpheniram

2008
Multiple H1-antihistamine-induced urticaria.
    The Journal of dermatology, 2009, Volume: 36, Issue:4

    Topics: Administration, Oral; Adult; Drug Eruptions; Female; Histamine; Histamine H1 Antagonists; Humans; Im

2009
Allergies in India: a study on medication compliance.
    Journal of the Indian Medical Association, 2009, Volume: 107, Issue:7

    Topics: Adolescent; Adult; Anti-Allergic Agents; Asthma; Bronchodilator Agents; Budesonide; Child; Ethanolam

2009
Urticaria due to antihistamines.
    Journal of investigational allergology & clinical immunology, 2011, Volume: 21, Issue:1

    Topics: Administration, Oral; Butyrophenones; Diagnosis, Differential; Drug Hypersensitivity; Female; Histam

2011
Effects of bepotastine and fexofenadine on histamine-induced flare, wheal and itch.
    International archives of allergy and immunology, 2012, Volume: 158, Issue:2

    Topics: Adult; Female; Histamine; Histamine H1 Antagonists, Non-Sedating; Humans; Male; Piperidines; Pruritu

2012
Chronic urticaria and angioedema.
    The New England journal of medicine, 2002, Jul-18, Volume: 347, Issue:3

    Topics: Angioedema; Chronic Disease; Histamine H1 Antagonists; Humans; Terfenadine; Urticaria

2002
In vivo anti-inflammatory effects of fexofenadine in chronic idiopathic urticaria.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2002, Volume: 16, Issue:4

    Topics: Adolescent; Adult; Biopsy, Needle; Case-Control Studies; Chronic Disease; Culture Techniques; E-Sele

2002
Solar urticaria induced by infrared radiation.
    Clinical and experimental dermatology, 2003, Volume: 28, Issue:2

    Topics: Female; Histamine H1 Antagonists; Humans; Infrared Rays; Middle Aged; PUVA Therapy; Terfenadine; Urt

2003
Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria.
    Health and quality of life outcomes, 2005, May-20, Volume: 3

    Topics: Adolescent; Adult; Aged; Child; Chronic Disease; Clinical Trials, Phase III as Topic; Data Interpret

2005
Assessing the therapeutic benefits of antihistamines for the treatment of chronic idiopathic urticaria--a requirement for well-designed comparative clinical studies.
    The Journal of dermatological treatment, 2005, Volume: 16, Issue:3

    Topics: Cetirizine; Histamine H1 Antagonists, Non-Sedating; Humans; Terfenadine; Treatment Outcome; Urticari

2005
Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2005, Volume: 54, Issue:9

    Topics: Animals; Cetirizine; CHO Cells; Cricetinae; Cricetulus; Histamine H1 Antagonists; Humans; Loratadine

2005
Formaldehyde-induced urticarial vasculitis.
    The Australasian journal of dermatology, 2007, Volume: 48, Issue:3

    Topics: Adult; Drug Therapy, Combination; Formaldehyde; Glucocorticoids; Histamine H1 Antagonists, Non-Sedat

2007
Antihistamine and sodium cromoglycate medication for food cold water exercise-induced anaphylaxis.
    Allergy, 2007, Volume: 62, Issue:12

    Topics: Adolescent; Anaphylaxis; Anti-Asthmatic Agents; Cold Temperature; Cromolyn Sodium; Drug Therapy, Com

2007
Non-interventional study comparing treatment satisfaction in patients treated with antihistamines.
    Clinical drug investigation, 2008, Volume: 28, Issue:4

    Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Aged, 80 and over; Cetirizine; Child;

2008
[Further development of terfenadine].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1997, Volume: 48, Issue:8 Suppl

    Topics: Clinical Trials as Topic; Histamine Antagonists; Histamine H1 Antagonists; Humans; Hypersensitivity,

1997
Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria.
    Drugs, 2000, Volume: 59, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Anti-Allergic Agents; Chronic Disease; Dose-Response Relati

2000
Fixed solar urticaria to visible light successfully treated with fexofenadine.
    Photodermatology, photoimmunology & photomedicine, 2001, Volume: 17, Issue:1

    Topics: Anti-Allergic Agents; Female; Humans; Middle Aged; Sunlight; Terfenadine; Ultraviolet Rays; Urticari

2001